TABLE 5.
Lersivirine activity against different HIV-1 cladesa
| HIV-1 clade (n) | Geographical origin(s) | Lersivirine activity |
|
|---|---|---|---|
| EC50 fold change | 95% CI range | ||
| A (A1, AE, AG) (6) | Australia, Canada, Netherlands, Poland, South Africa, United Kingdom | 1.12 | 0.89-1.40 |
| B (5) | Australiad, Canada, Poland, United States | 0.82 | 0.54-1.26 |
| BF (5) | Argentinae | 1.02b | 0.51-2.02 |
| C (25) | South Africaf, Australia, Canada, Puerto Rico, United Kingdom, United States | 1.07c | 0.88-1.30 |
| CH (1) | South Africa | 0.62 | NA |
| D (1) | United Kingdom | 1.02 | NA |
| F1 (1) | Argentina | 1.54 | NA |
| G (1) | United Kingdom | 1.05 | NA |
| Total (45) | 1.03 | 0.91-1.18 | |
a
Sensitivity of clinically derived virus isolates representing different viral subtypes from treatment-naïve patients to lersivirine. Lersivirine was profiled against 45 cloned clinical isolates in Monogram Bioscience's PhenoSense assay. Geometric mean EC50 fold changes from that for the wt reference virus are reported with 95% confidence interval (CI) ranges. NA, not available.
b
One circulating recombinant form BF virus showed an EC50 fold change of 2.3.
c
One clade C virus showed an EC50 fold change of 6.3.
d
Two clade B viruses tested from Australia.
e
Five clade BF viruses tested from Argentina.
f
Twenty clade C viruses tested from South Africa.